MEDICENNA THERAPEUTICS CORP.
2 Bloor St. W., 7th Floor
Toronto, Ontario M4W 3E2
February 23, 2023
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
|RE:||Medicenna Therapeutics Corp.|
|Registration Statement on Form F-3|
|Filed February 17, 2023|
|File No. 333- 269868|
Dear Mr. Crawford:
With respect to the above-referenced Registration Statement on Form F-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of Medicenna Therapeutics Corp. (the “Company”), that the Securities and Exchange Commission accelerate the effective date of the Registration Statement to February 27, 2023, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call John Rudy and Keunjung Cho of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 542-6000, with any comments or questions regarding the Registration Statement.
|Very truly yours,|
|MEDICENNA THERAPEUTICS CORP.|
|/s/ Elizabeth Williams|
|Chief Financial Officer|
|cc:||Elizabeth Williams, Medicenna Therapeutics Corp.|
|John Rudy, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.|
|Keunjung Cho, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.|